Annals of oncology : official journal of the European Society for Medical Oncology · 2008
Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shivakumar R, Tan W, Wilding G E, Wang E S, Wetzler M
Аннотация
BACKGROUND: Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well characterized.
PATIENTS AND METHODS: We describe a cohort of seven patients and discuss 94 additional cases from the literature for whom biological parameters were described. Cases with incomplete data were excluded.
RESULTS: Hodgkin's disease (HD) was more common in the 18-59 age group while breast and prostate cancers were prevalent only in the >or=18-year-old patients. The time interval to develop sALL was similar among all age groups but was significantly longer for HD and neuroblastoma primary diagnoses and sALL with complex karyotype. T-cell immunophenotype was more common in the <18 age group. Complete remission was infrequent in the >or=60 age group. The overall survival was poor for all sALL regardless of age, primary diagnoses, cytogenetic subgroups, or immunophenotype. Allogeneic transplantation most probably represents the only chance of cure.
CONCLUSION: Better identification of prognostic factors to prevent the occurrence of sALL is indicated.
PATIENTS AND METHODS: We describe a cohort of seven patients and discuss 94 additional cases from the literature for whom biological parameters were described. Cases with incomplete data were excluded.
RESULTS: Hodgkin's disease (HD) was more common in the 18-59 age group while breast and prostate cancers were prevalent only in the >or=18-year-old patients. The time interval to develop sALL was similar among all age groups but was significantly longer for HD and neuroblastoma primary diagnoses and sALL with complex karyotype. T-cell immunophenotype was more common in the <18 age group. Complete remission was infrequent in the >or=60 age group. The overall survival was poor for all sALL regardless of age, primary diagnoses, cytogenetic subgroups, or immunophenotype. Allogeneic transplantation most probably represents the only chance of cure.
CONCLUSION: Better identification of prognostic factors to prevent the occurrence of sALL is indicated.
Предметные рубрики MeSH
AdolescentAdultAge FactorsAnalysis of VarianceAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleCause of DeathCohort StudiesCombined Modality TherapyFemaleHodgkin DiseaseHumansImmunohistochemistryKaplan-Meier EstimateLeukemia, MyeloidMaleMiddle AgedNeoplasm StagingNeoplasms, Second PrimaryPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRisk FactorsSex FactorsStatistics, NonparametricStem Cell TransplantationSurvival AnalysisTreatment Outcome